

10/535,690

Connecting via Winsock to STN

Welcome to STN International! Enter x::x

LOGINID: ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4 AUG 24 ENCOMPPLIT/ENCOMPPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/Caplus enhanced with legal status information for U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:26:58 ON 16 OCT 2009

=> file reg
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:27:05 ON 16 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

10/535,690

provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2009 HIGHEST RN 1188475-73-1
DICTIONARY FILE UPDATES: 15 OCT 2009 HIGHEST RN 1188475-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10535690NEW3.str



chain nodes :
 6 7 8 9 10 11 13 14 15 16 17 18 24 26 27 28 34 40 42 43 45 46
 49
 ring nodes :
 1 2 3 4 5 12 19 20 21 22 23
 chain bonds :
 1-7 3-9 4-8 5-6 7-40 9-42 11-12 13-14 13-15 13-16 13-43 16-17 16-18
 26-27 27-28 45-46
 ring bonds :
 1-2 1-5 2-3 3-4 4-5 12-19 12-23 19-20 20-21 21-22 22-23
 exact/norm bonds :
 1-2 1-5 1-7 2-3 3-4 4-5 4-8 7-40 9-42 11-12 13-14 13-15 13-16 13-43
 16-18 45-46
 exact bonds :
 3-9 5-6 16-17 26-27 27-28

10/535,690

normalized bonds :
12-19 12-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 12 :

G1:[*1], [*2], [*3], [*4], [*5]

G2:[*6], [*7], [*8]

Connectivity :
11:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:CLASS 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 26:CLASS 27:CLASS 28:CLASS
34:Atom 40:CLASS 42:CLASS 43:Atom 45:Atom 46:Atom 49:Atom

Generic attributes :

10:

Saturation : Saturated

18:

Saturation : Unsaturated

Number of Hetero Atoms : Exactly 1

Type of Ring System : Monocyclic

24:

Saturation : Unsaturated

Type of Ring System : Polycyclic

34:

Saturation : Unsaturated

Type of Ring System : Monocyclic

43:

Saturation : Unsaturated

Type of Ring System : Monocyclic

45:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

46:

Saturation : Saturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

49:

Saturation : Unsaturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

Element Count :

Node 11: Limited

C,Cl-3

Node 18: Limited

N,N1

C,C5

O,O0

S,S0

Node 24: Limited

N,NO-3

O,OO-2

S,SO-1

10/535, 690

Node 34: Limited
N, N0-1
S, S0-1

Node 43: Limited
C,C6
O,OO
S,SO
N,NO

Node 45: Limited
C,C6
O,OO
S,SO
N,NO

Node 46: Limited
N, N2
C, C4
O, O0
S, S0

Node 49: Limited
C,C10
O,O0
S,S0
N,N0

L1 STRUCTURE UPLOADED

```
=> d 11
L1 HAS NO ANSWERS
L1                      STR
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFF-LINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sss sam
SAMPLE SEARCH INITIATED 12:27:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      4612 TO ITERATE
```

43.4% PROCESSED 2000 ITERATIONS 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJECTED ITERATIONS: 88167 TO 96313
PROJECTED ANSWERS: 142 TO 688


L2 9 SEA SSS SAM L1

10/535,690

=> d scan

10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 2-(cyclopentylamino)-5-[(5-(4-fluorophenyl)-2-
thienyl)methylene]-
MF C19 H17 F N2 O S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8


L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 4(5H)-Thiazolone, 5-[(2-amino-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, (5Z)-, 2,2,2-trifluoroacetate (1:1)
 MF C22 H18 N4 O S . C2 H F3 O2

CM 1

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2



10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 2-[(2-(4-aminophenyl)ethyl]amino]-5-(6-
quinolinylmethylene)-, (5Z)-
MF C21 H18 N4 O S

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 2-[(3,5-dimethylphenyl)methyl]amino-5-[(1-(4-
fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methylene]-
MF C25 H24 F N3 O S

PAGE 1-A




PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/535,690


L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 5-[(7-chloro-1,3-benzodioxol-5-yl)methylene]-2-
(cyclohexylamino)-
MF C17 H17 Cl N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(6-fluoro-4H-1,3-benzodioxin-8-
yl)methylene]-
MF C18 H19 F N2 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxamide, 4-methoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl]-
MF C24 H20 N4 O3 S


Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 5-[(1-[(4-chlorophenyl)methyl]-1H-indol-3-yl)methylene]-
2-(1-naphthalenylamino)-
MF C29 H20 Cl N3 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/535,690

L2 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4(5H)-Thiazolone, 5-[1-(3,5-dimethylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]methylene]-2-[(3,5-dimethylphenyl)methyl]amino]-
MF C27 H29 N3 O S

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/535,690

=> s 11 sss ful
FULL SEARCH INITIATED 12:28:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 94487 TO ITERATE

100.0% PROCESSED 94487 ITERATIONS 323 ANSWERS
SEARCH TIME: 00.00.03

L3 323 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
186.36 186.58

FILE 'CAPLUS' ENTERED AT 12:28:34 ON 16 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2009 VOL 151 ISS 17
FILE LAST UPDATED: 15 Oct 2009 (20091015/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 31 L3
=> d 14 1-31 bib hitstr

L4 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:773310 CAPLUS
 DN 151:173293
 TI Cell Division Cycle 7 Kinase Inhibitors: 1H-Pyrrolo[2,3-b]pyridines, Synthesis and Structure-Activity Relationships
 AU Ermoli, Antonella; Bargiotti, Alberto; Brasca, Maria Gabriella; Ciavolella, Antonella; Colombo, Nicoletta; Fachin, Gabriele; Isacchi, Antonella; Menichincheri, Maria; Molinari, Antonio; Montagnoli, Alessia; Pillan, Antonio; Rainoldi, Sonia; Sirtori, Federico Riccardi; Sola, Francesco; Thieffine, Sandrine; Tibolla, Marcellino; Valsasina, Barbara; Volpi, Daniele; Santocanale, Corrado; Vanotti, Ermes
 CS Nerviano Medical Sciences, Milan, 20014, Italy
 SO Journal of Medicinal Chemistry (2009), 52(14), 4380-4390
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 IT 937011-35-3P 1173715-54-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and structure-activity relationships of pyrrolopyridine derivs. as Cdc7 kinase inhibitors)
 RN 937011-35-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(1S)-1-phenylethyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, hydrochloride (1:1), (5Z)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● HCl

RN 1173715-54-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(phenylmethyl)amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, hydrochloride (1:1), (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:1462272 CAPLUS
 DN 150:168212
 TI Three-component one-pot synthetic route to
 2-amino-5-alkylidene-thiazol-4-ones
 AU Anderluh, Marko; Jukic, Marko; Petric, Rok
 CS Department of Medicinal Chemistry, Faculty of Pharmacy, University of
 Ljubljana, Ljubljana, 1000, Slovenia
 SO Tetrahedron (2008), Volume Date 2009, 65(1), 344-350
 CODEN: TETRAB; ISSN: 0040-4020
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 150:168212
 IT 1105571-73-0P 1105572-07-3P 1107591-69-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective preparation of amino alkylidene thiazolones via subsequent
 Knoevenagel condensation and addition-elimination of aryl/heteroaryl
 aldehydes, rhodanine and primary/cyclic amines)
 RN 1105571-73-0 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(phenylmethyl)amino]-5-(2-thienylmethylene)-, (5Z)-
 (CA INDEX NAME)

Double bond geometry as shown.




RN 1105572-07-3 CAPLUS
 CN 4(5H)-Thiazolone, 5-(1H-indol-3-ylmethylene)-2-[(phenylmethyl)amino]-,
 (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1107591-69-4 CAPLUS
 CN 4(5H)-Thiazolone, 5-(1,3-benzodioxol-5-ylmethylene)-2-
 [(phenylmethyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:1022578 CAPLUS
 DN 147:365484
 TI Preparation of thiazolones for use as PI3 kinase inhibitors
 IN Dhanak, Dashyant; Knight, Steven David
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 129 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007103755	A2	20070913	WO 2007-US63113	20070302
	WO 2007103755	A3	20080306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1993536		A2	20081126	EP 2007-757756	20070302
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2009528384		T	20090806	JP 2008-557506	20070302
US 20090048252		A1	20090219	US 2008-281181	20080829
PRAI US 2006-778272P		P	20060302		
WO 2007-US63113		W	20070302		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:365484

IT 864274-24-8P 864274-25-9P 864274-26-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted thiazolones as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 864274-24-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(trans-4-hydroxycyclohexyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry unknown.




RN 864274-25-9 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)



RN 864274-26-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[(4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl]amino]ethyl]- (CA INDEX NAME)




L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:1022549 CAPLUS
 DN 147:365483
 TI Preparation of thiazolones for use as PI3 kinase inhibitors
 IN Dhanak, Dashyant; Knight, Steven David
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103754	A2	20070913	WO 2007-US63112	20070302
WO 2007103754	A3	20080306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1993535	A2	20081126	EP 2007-757755	20070302
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2009528383	T	20090806	JP 2008-557505	20070302
US 20090023742	A1	20090122	US 2008-281179	20080829
PRAI US 2006-778428P	P	20060302		
WO 2007-US63112	W	20070302		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS CASREACT 147:365483; MARPAT 147:365483
 IT 701293-25-6P 701293-26-7P 701293-38-1P
 701293-78-9P 701293-80-3P 701294-12-4P
 701294-16-8P 701294-17-9P 701294-18-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of thiazolone compds. as PI3 kinase inhibitors useful in
 combination therapy of diseases)


RN 701293-25-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(2,3-dihydro-1,4-benzodioxin-6-
 yl)methylene]- (CA INDEX NAME)




RN 701293-26-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(2,3-dihydro-5-
 benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-38-1 CAPLUS
CN 4(5H)-Thiazolone, 2-(1-naphthalenylamino)-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-78-9 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 701293-80-3 CAPLUS
CN Benzenesulfonamide, 4-[[[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]methyl]- (CA INDEX NAME)




RN 701294-12-4 CAPLUS
CN Benzenesulfonamide, 4-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]-N-2-pyridinyl- (CA INDEX NAME)




RN 701294-16-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-(4-methyl-1-piperazinyl)phenyl)amino]-5-(6-quinolinylimethylene)- (CA INDEX NAME)




RN 701294-17-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-(3-chlorophenyl)ethyl)amino]-5-(6-quinolinylimethylene)- (CA INDEX NAME)




RN 701294-18-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[(4,5-dihydro-4-oxo-5-(6-quinolinylimethylene)-2-thiazolyl)amino]ethyl]- (CA INDEX NAME)



L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:538983 CAPLUS
 DN 146:521783
 TI Pyrrolopyridines as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases linked to disregulated cell proliferation or disregulated protein kinase
 IN Vanotti, Ermes; Angelucci, Francesco; Bargiotti, Alberto; Brasca, Maria Gabriella; Ermoli, Antonella; Menichincheri, Maria
 PA Pfizer Italia Srl, Italy
 SO PCT Int. Appl., 118pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007054508	A1	20070518	WO 2006-EP68220	20061108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 200701112020	A1	20070517	US 2005-271191	20051111
US 7371862	B2	20080513		
CA 2629228	A1	20070518	CA 2006-2629228	20061108
EP 1960399	A1	20080827	EP 2006-819327	20061108
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009515849	T	20090416	JP 2008-539427	20061108
MX 200806174	A	20080522	MX 2008-6174	20080509
PRAI US 2005-271191	A	20051111		
WO 2006-EP68220	W	20061108		
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OS MARPAT 146:521783				
IT 937011-34-2P	937011-35-3P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(drug candidate; preparation of pyrrolopyridine compds. as kinase inhibitors useful in treatment of diseases linked to disregulated cell proliferation or to disregulated protein kinase)				
RN 937011-34-2	CAPLUS			
CN 4(5H)-Thiazolone, 2-[(phenylmethyl)amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, hydrochloride (1:1)	(CA INDEX NAME)			




● HCl

RN 937011-35-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(1S)-1-phenylethyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, hydrochloride (1:1), (52)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● HCl


OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:382117 CAPLUS
 DN 147:52839
 TI Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors
 AU Chen, Shaqing; Chen, Li; Le, Nam T.; Zhao, Chunlin; Sidduri, Achyutharao; Lou, Jian Ping; Michoud, Christophe; Portland, Louis; Jackson, Nicole; Liu, Jin-Jun; Konzelmann, Fred; Chi, Feng; Tovar, Christian; Xiang, Qing; Chen, Yingsi; Wen, Yang; Vassilev, Lyubomir T.
 CS Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(8), 2134-2138
 CODEN: BMCL8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 147:52839
 IT 872573-97-2P 872574-03-3P 872574-04-4P
 872574-05-5P 872574-16-8P 938047-12-2P
 938047-14-4P 938047-15-5P 938047-16-6P
 938047-18-8P 938047-20-2P 938047-21-3P
 938047-22-4P 938047-23-5P 938047-24-6P
 938047-25-7P 938047-26-8P 938047-27-9P
 938047-28-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, cyclin-dependent kinase 1 inhibitory activity, antitumor activity, and SAR of (quinolinylmethylene)thiazolinones)
 RN 872573-97-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-(4-methoxyphenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 872574-03-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-(2-ethoxyphenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-04-4 CAPLUS

10/535,690

CN 4(5H)-Thiazolone, 2-[(2-methoxyphenyl)methyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872574-05-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-methoxyphenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-16-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(1R,2S)-2-phenylcyclopropyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 938047-12-2 CAPLUS


CN 4(5H)-Thiazolone, 2-(cyclopropylamino)-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 938047-14-4 CAPLUS
CN 4(SH)-Thiazolone, 2-[(phenylmethyl)amino]-5-(6-quinolinylmethylene)-,
(5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 938047-15-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-phenylethyl)amino]-5-(6-quinolinylmethylene)-,
(5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 938047-16-6 CAPLUS
CN 4(5H)-Thiazolone, 2-[(3-phenylpropyl)amino]-5-(6-quinolinylmethylene)-,
(5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 938047-18-8 CAPLUS

10/535,690

CN 4(5H)-Thiazolone, 2-[[2-(2-fluorophenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 938047-20-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2-(3-fluorophenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 938047-21-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2-(4-fluorophenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 938047-22-4 CAPLUS


CN 4(5H)-Thiazolone, 2-[[2-(4-chlorophenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 938047-23-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(4-bromophenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 938047-24-6 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(3-chlorophenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 938047-25-7 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(2-chlorophenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 938047-26-8 CAPLUS

10/535,690

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 938047-27-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-bromophenyl)methyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 938047-28-0 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)methyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:1225881 CAPLUS
 DN 146:7948
 TI Preparation of 2,5-disubstituted thiazol-4-ones as vanilloid receptor VR1 ligands.

IN Frank, Robert; Kless, Achim; Jostock, Ruth

PA Gruenenthal G.m.b.H., Germany

SO PCT Int. Appl., 153pp.


CODEN: PIXXD2

DT Patent


LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006122777	A2	20061123	WO 2006-EP4666	20060517
	WO 2006122777	A3	20070222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	DE 102005024012	A1	20061123	DE 2005-102005024012	20050520
	CA 2609002	A1	20061123	CA 2006-2609002	20060517
	EP 1890695	A2	20080227	EP 2006-753682	20060517
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
	JP 2008540595	T	20081120	JP 2008-511622	20060517
	US 20090215758	A1	20090827	US 2008-915156	20080610
PRAI	DE 2005-102005024012	A	20050520		
	WO 2006-EP4666	W	20060517		
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT					
OS	CASREACT	146:7948; MARPAT	146:7948		
IT	915312-05-9	915312-09-3	915312-15-1		
	915312-20-8				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)					
(preparation of thiazolones as vanilloid receptor VR1 ligands)					
RN	915312-05-9	CAPLUS			
CN	4(5H)-Thiazolone, 2-[(4-methylphenyl)methyl]amino]-5-(1-naphthalenylmethylene)-	-	(CA INDEX NAME)		




RN 915312-09-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(4-methylphenyl)methyl]amino-5-(2-naphthalenylmethylene)- (CA INDEX NAME)



RN 915312-15-1 CAPLUS
CN 4(5H)-Thiazolone, 5-(1-naphthalenylmethylene)-2-[(4-(trifluoromethyl)phenyl)methyl]amino- (CA INDEX NAME)




RN 915312-20-8 CAPLUS
CN 4(5H)-Thiazolone, 5-(2-naphthalenylmethylene)-2-[(4-(trifluoromethyl)phenyl)methyl]amino- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:1041058 CAPLUS
 DN 145:397520
 TI Preparation of substituted 1,5-naphthyridine azolinones
 IN Liu, Jin-Jun
 PA Hoffmann-La Roche Inc., USA
 SO U.S. Pat. Appl. Publ., 27 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20060223843	A1	20061005	US 2006-368936	20060306
US 7304074	B2	20071204		
AU 2006232747	A1	20061012	AU 2006-232747	20060324
CA 2602757	A1	20061012	CA 2006-2602757	20060324
WO 2006106046	A1	20061012	WO 2006-EP61027	20060324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1869036	A1	20071226	EP 2006-708812	20060324
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008534646	T	20080828	JP 2008-504732	20060324
MX 2007011982	A	20071210	MX 2007-11982	20070927
CN 101155808	A	20080402	CN 2006-80011124	20070930
KR 2007112239	A	20071122	KR 2007-722761	20071005
IN 2007CN04389	A	20080125	IN 2007-CN4389	20071005
PRAI US 2005-668246P	P	20050405		
WO 2006-EP61027	W	20060324		
OS CASREACT 145:397520; MARPAT 145:397520				
IT 911389-15-6P				
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of [1,5]-naphthyridine azolinones, their Cdk-1, -2, and -4 inhibitory activity, and antitumor activity)				
RN 911389-15-6 CAPLUS				
CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-chloro-6- methylphenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene)methyl]- (CA INDEX NAME)				




IT 911389-00-9P 911389-03-2P 911389-04-3P
 911389-05-4P 911389-10-1P 911389-13-4P
 911389-14-5P 911389-16-7P 911389-17-8P
 911389-19-0P 911389-23-6P 911389-25-8P
 911389-26-9P 911389-27-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of [1,5]-naphthyridine azolinones, their Cdk-1, -2, and -4 inhibitory activity, and antitumor activity)

RN 911389-00-9 CAPLUS


CN 1,5-Naphthyridine-3-carbonitrile, 4-(1-methylethoxy)-6-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 911389-03-2 CAPLUS

CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-chloro-6-methylphenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene)methyl]-4-(1-methylethoxy)- (CA INDEX NAME)




RN 911389-04-3 CAPLUS

CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-(3-fluorophenyl)ethyl]amino)-4-oxo-5(4H)-thiazolylidene)methyl]-4-(1-methylethoxy)- (CA INDEX NAME)




RN 911389-05-4 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-chloro-4-fluorophenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-(1-methylethoxy)- (CA INDEX NAME)




RN 911389-10-1 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino)-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.




RN 911389-13-4 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-(3-fluorophenyl)ethyl]amino)-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)




RN 911389-14-5 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-chlorophenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)



RN 911389-16-7 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-chloro-4-fluorophenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene]methyl- (CA INDEX NAME)




RN 911389-17-8 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(3-chloro-4-fluorophenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene]methyl- (CA INDEX NAME)




RN 911389-19-0 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(8-(1-methylethoxy)-1,5-naphthyridin-2-yl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.




RN 911389-23-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-(3-fluorophenyl)ethyl]amino)-5-[(8-(1-methylethoxy)-1,5-naphthyridin-2-yl)methylene]- (CA INDEX NAME)




RN 911389-25-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-[(8-(1-methylethoxy)-1,5-naphthyridin-2-yl)methylene]- (CA INDEX NAME)




RN 911389-26-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(3-chloro-4-fluorophenyl)methyl]amino]-5-[(8-(1-methylethoxy)-1,5-naphthyridin-2-yl)methylene]- (CA INDEX NAME)



RN 911389-27-0 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)methyl]amino]-5-[(8-(1-methylethoxy)-1,5-naphthyridin-2-yl)methylene]- (CA INDEX NAME)



IT 911388-99-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of [1,5]-naphthyridine azolinones, their Cdk-1, -2, and -4 inhibitory activity, and antitumor activity)
 RN 911388-99-3 CAPLUS
 CN 1,5-Naphthyridine-3-carbonitrile, 6-[(2-[(2-chlorophenyl)methyl]amino)-4-oxo-5(4H)-thiazolylidene)methyl]-4-(1-methylethoxy)- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:367076 CAPLUS

DN 144:398358

TI PI3 kinase gamma inhibitors for the treatment of anaemia
 IN Wetzker, Reinhard; Mueller, Angelika; Rommel, Christian
 PA Applied Research Systems Ars Holding N.V., Neth. Antilles
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006040318	A2	20060420	WO 2005-EP55156	20051011
	WO 2006040318	A3	20060810		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005293556	A1	20060420	AU 2005-293556	20051011
	CA 2580480	A1	20060420	CA 2005-2580480	20051011
	EP 1807075	A2	20070718	EP 2005-801722	20051011
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101056633	A	20071017	CN 2005-80038804	20051011
	JP 2008515955	T	20080515	JP 2007-536166	20051011
	ZA 2007002435	A	20080625	ZA 2007-2435	20051011
	BR 2005017416	A	20081007	BR 2005-17416	20051011
	IN 2007DN02450	A	20070803	IN 2007-DN2450	20070402
	MX 2007004302	A	20070607	MX 2007-4302	20070411
	NO 2007002393	A	20070509	NO 2007-2393	20070509
	US 20090042773	A1	20090212	US 2007-664969	20070710
PRAI	EP 2004-104997	A	20041012		
	WO 2005-EP55156	W	20051011		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:398358


IT 843641-27-0 843641-28-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PI3 kinase gamma inhibitors for treatment of anemia)

RN 843641-27-0 CAPLUS


CN 4(5H)-Thiazolone, 5-(1,3-benzodioxol-5-ylmethylene)-2-[(phenylmethyl)amino]- (CA INDEX NAME)



10/535,690

RN 843641-28-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(phenylmethyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:365138 CAPLUS
 DN 144:412492
 TI Preparation of azaindole thiazolinones as anti-cancer agents
 IN Chen, Shaqing; Sidduri, Achyutharao
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006040049	A1	20060420	WO 2005-EP10702	20051005
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005293831	A1	20060420	AU 2005-293831	20051005
	CA 2582986	A1	20060420	CA 2005-2582986	20051005
	US 20060084674	A1	20060420	US 2005-243855	20051005
	US 7247727	B2	20070724		
	EP 1805175	A1	20070711	EP 2005-796364	20051005
	EP 1805175	B1	20080305		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101039943	A	20070919	CN 2005-80034649	20051005
	AT 388149	T	20080315	AT 2005-796364	20051005
	JP 2008516903	T	20080522	JP 2007-536044	20051005
	ES 2301066	T3	20080616	ES 2005-796364	20051005
	BR 2005018158	A	20081104	BR 2005-18158	20051005
	MX 2007004273	A	20070511	MX 2007-4273	20070411
	KR 2007053342	A	20070523	KR 2007-708500	20070413
	KR 875870	B1	20081226		
	IN 2007CN01491	A	20070831	IN 2007-CN1491	20070413
PRAI	US 2004-618672P	P	20041014		
	WO 2005-EP10702	W	20051005		
OS	CASREACT 144:412492; MARPAT 144:412492				
IT	883874-11-1P, (Z)-2-[(3-Chloro-4-fluorobenzyl)amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one				
	883874-12-2P, (Z)-2-[(1R,2S)-2-Phenylcyclopropyl)amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one				
	883874-17-7P, (Z)-2-[(2-Chlorobenzyl)amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one 883874-18-8P, (Z)-2-[(2-Chloro-6-methylbenzyl)amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one 883874-21-3P, (Z)-2-[(2-Chloro-4-fluorobenzyl)amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one 883874-25-7P, (Z)-2-[(3-Fluorophenyl)ethyl]amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one 883874-26-8P, (Z)-2-Cyclopropylamino-5-[1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]thiazol-4-one				


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridinyl thiazolinones as anti-cancer agents)

RN 883874-11-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(3-chloro-4-fluorophenyl)methyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 883874-12-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[(1R,2S)-2-phenylcyclopropyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 883874-17-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 883874-18-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-6-methylphenyl)methyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 883874-21-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)methyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 883874-25-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-(3-fluorophenyl)ethyl]amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 883874-26-8 CAPLUS

CN 4(5H)-Thiazolone, 2-(cyclopropylamino)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CALPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:365055 CAPLUS
 DN 144:412488
 TI Preparation of [1,5]naphthyridine azothiazolones as CDK1 antiproliferative agents
 IN Liu, Jin-Jun
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006040052	A1	20060420	WO 2005-EP10716	20051005
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005293835	A1	20060420	AU 2005-293835	20051005
	CA 2583192	A1	20060420	CA 2005-2583192	20051005
	US 20060084673	A1	20060420	US 2005-244022	20051005
	US 7268231	B2	20070911		
	EP 1805174	A1	20070711	EP 2005-791894	20051005
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101039944	A	20070919	CN 2005-80035111	20051005
	JP 2008516905	T	20080522	JP 2007-536046	20051005
	BR 2005016488	A	20080909	BR 2005-16488	20051005
	MX 2007004276	A	20070516	MX 2007-4276	20070411
	KR 2007053332	A	20070523	KR 2007-708407	20070413
	KR 875408	B1	20081223		
	IN 2007CN011522	A	20070831	IN 2007-CN1522	20070416
	KR 2008075235	A	20080814	KR 2008-718586	20080728
PRAI	US 2004-618807P	P	20041014		
	WO 2005-EP10716	W	20051005		
	KR 2007-708407	A3	20070413		
OS	CASREACT 144:412488; MARPAT 144:412488				
IT	883865-01-8P 883865-06-3P 883865-12-1P, 2-[(3-Chloro-4-fluorobenzyl)amino]-5-[(1,5)naphthyridin-2-yl)methylene]thiazol-4-one 883865-15-4P, 2-[(2-(3-Fluorophenyl)ethyl)amino]-5-[(1,5)naphthyridin-2-yl)methylene]thiazol-4-one 883865-17-6P, 2-[(2-Chloro-6-methylbenzyl)amino]-5-[(1,5)naphthyridin-2-yl)methylene]thiazol-4-one 883865-19-8P, 2-[(2-Chloro-4-fluorobenzyl)amino]-5-[(1,5)naphthyridin-2-yl)methylene]thiazol-4-one				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of [1,5]naphthyridine azothiazolones as CDK1 antiproliferative agents)				


10/535,690

RN 883865-01-8 CAPLUS
CN 4(5H)-Thiazolone, 2-(1,5-naphthyridin-2-ylmethylene)-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.




RN 883865-06-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-(1,5-naphthyridin-2-ylmethylene)- (CA INDEX NAME)




RN 883865-12-1 CAPLUS
CN 4(5H)-Thiazolone, 2-[(3-chloro-4-fluorophenyl)methyl]amino]-5-(1,5-naphthyridin-2-ylmethylene)- (CA INDEX NAME)



RN 883865-15-4 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(3-fluorophenyl)ethyl]amino]-5-(1,5-naphthyridin-2-ylmethylene)- (CA INDEX NAME)




RN 883865-17-6 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chloro-6-methylphenyl)methyl]amino]-5-(1,5-naphthyridin-2-ylmethylene)- (CA INDEX NAME)



RN 883865-19-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)methyl]amino]-5-(1,5-naphthyridin-2-ylmethylene)- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:362447 CAPLUS
 DN 144:412525
 TI Preparation of quinazolinylmethylene thiazolinones as CDK1 inhibitors
 IN Chen, Li; Chen, Shaqing; Liu, Jin-Jun
 PA F.Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 69 PP.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006040050	A1	20060420	WO 2005-EP10703	20051005
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU	2005293832	A1	20060420	AU 2005-293832	20051005
CA	2583311	A1	20060420	CA 2005-2583311	20051005
US	20060084804	A1	20060420	US 2005-244028	20051005
US	7501428	B2	20090310		
EP	1802614	A1	20070704	EP 2005-794407	20051005
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN	101039939	A	20070919	CN 2005-80034902	20051005
JP	2008516904	T	20080522	JP 2007-536045	20051005
BR	2005018164	A	20081104	BR 2005-18164	20051005
MX	2007004274	A	20070516	MX 2007-4274	20070411
KR	2007053343	A	20070523	KR 2007-708501	20070413
KR	890533	B1	20090327		
IN	2007CN01498	A	20070831	IN 2007-CN1498	20070413
PRAI	US 2004-618612P	P	20041014		
	US 2005-681079P	P	20050513		
	WO 2005-EP10703	W	20051005		
OS	CASREACT 144:412525				
IT	883867-29-6P, (Z)-2-[(2-(3-Fluorophenyl)ethyl]amino]-5-[1-(quinazolin-6-yl)methylidene]thiazol-4-one 883867-34-3P, (Z)-2-[(3-Fluorobenzyl)amino]-5-[1-(quinazolin-6-yl)methylidene]thiazol-4-one 883867-36-5P, (Z)-5-[1-(4-Ethoxyquinazolin-6-yl)methylidene]-2-[2-(3-fluorophenyl)ethyl]amino]thiazol-4-one 883867-39-8P 883867-44-5P, 2-[(2-Chlorobenzyl)amino]-5-[(4-ethoxy-2-(methylamino)quinazolin-6-yl)methylene]thiazol-4-one 883867-47-8P, 2-[(3-Chloro-4-fluorobenzyl)amino]-5-[(4-ethoxy-2-(methylamino)quinazolin-6-yl)methylene]thiazol-4-one 883867-48-9P, 2-[(2-Chloro-4-fluorobenzyl)amino]-5-[(4-ethoxy-2-(methylamino)quinazolin-6-yl)methylene]thiazol-4-one 883867-49-0P, 2-[(2-Chloro-6-methylbenzyl)amino]-5-[(4-ethoxy-2-(methylamino)quinazolin-6-yl)methylene]thiazol-4-one 883867-51-4P, 5-[(4-Ethoxy-2-(methylamino)quinazolin-6-yl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]thiazol-4-one 883867-57-0P,				

2-[[2-(3-Fluorophenyl)ethyl]amino]-5-[1-(quinazolin-6-yl)methylidene]thiazol-4-one 883867-58-1P,
 2-[(3-Fluorobenzyl)amino]-5-[1-(quinazolin-6-yl)methylidene]thiazol-4-one 883867-59-2P, 5-[1-(4-Ethoxyquinazolin-6-yl)methylidene]-2-[(2-(3-fluorophenyl)ethyl)amino]thiazol-4-one 883867-61-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazolinylmethylene thiazolinones as CDK1 inhibitors for treatment of cancers)

RN 883867-29-6 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2-(3-fluorophenyl)ethyl]amino]-5-(6-quinazolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 883867-34-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(3-fluorophenyl)methyl]amino]-5-(6-quinazolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 883867-36-5 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-6-quinazolinyl)methylidene]-2-[(2-(3-fluorophenyl)ethyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 883867-39-8 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-2-(methylamino)-6-quinazolinyl)methylidene]-2-


[(1*R*,2*S*)-2-phenylcyclopropyl]amino]-, (5*Z*)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 883867-44-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-[(4-ethoxy-2-(methylamino)-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 883867-47-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(3-chloro-4-fluorophenyl)methyl]amino]-5-[(4-ethoxy-2-(methylamino)-6-quinazolinyl)methylene]- (CA INDEX NAME)



RN 883867-48-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)methyl]amino]-5-[(4-ethoxy-2-(methylamino)-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 883867-49-0 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-6-methylphenyl)methyl]amino]-5-[(4-ethoxy-


10/535,690

2-(methylamino)-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 883867-51-4 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-2-(methylamino)-6-quinazolinyl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]- (CA INDEX NAME)




RN 883867-57-0 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-(3-fluorophenyl)ethyl)amino]-5-(6-quinazolinyl)methylene]- (CA INDEX NAME)



RN 883867-58-1 CAPLUS


CN 4(5H)-Thiazolone, 2-[(3-fluorophenyl)methyl]amino]-5-(6-quinazolinyl)methylene]- (CA INDEX NAME)



RN 883867-59-2 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-6-quinazolinyl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]- (CA INDEX NAME)


10/535,690



RN 883867-61-6 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-2-(methylamino)-6-quinazolinyl)methylene]-2-[(2-phenylcyclopropyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:273697 CAPLUS
 DN 144:331426
 TI Preparation of quinolinyl thiazolinones as CDK1 inhibitors for treatment of cancers
 IN Chen, Li; Chen, Shaoqing; Michoud, Christophe
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006029863	A1	20060323	WO 2005-EP9927	20050915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US	20060063804	A1	20060323	US 2005-224175	20050912
US	7241893	B2	20070710		
AU	2005284294	A1	20060323	AU 2005-284294	20050915
CA	2579348	A1	20060323	CA 2005-2579348	20050915
EP	1791836	A1	20070606	EP 2005-788472	20050915
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN	101018785	A	20070815	CN 2005-80030902	20050915
JP	2008513398	T	20080501	JP 2007-531677	20050915
BR	2005015451	A	20080729	BR 2005-15451	20050915
MX	2007002721	A	20070423	MX 2007-2721	20070306
KR	2007043886	A	20070425	KR 2007-705967	20070315
KR	901091	B1	20090608		
IN	2007CN01146	A	20070817	IN 2007-CN1146	20070319
KR	2009031797	A	20090327	KR 2009-704678	20090305
PRAI	US 2004-610767P	P	20040917		
	WO 2005-EP9927	W	20050915		
	KR 2007-705967	A3	20070315		
OS	CASREACT 144:331426; MARPAT 144:331426				
IT	880144-54-7P 880144-55-8P 880144-62-7P, 5-[(2-Amino-4-ethoxyquinolin-6-yl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]thiazol-4-one 880144-70-7P, N-[6-[(2-(Cyclopropylamino)-4-oxo-4H-thiazol-5-ylidene)methyl]-4-ethoxyquinolin-2-yl]acetamide				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of quinolinyl thiazolinones as CDK1 inhibitors for treatment of cancers)				
RN	880144-54-7 CAPLUS				
CN	4(5H)-Thiazolone, 5-[(2-amino-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, (5Z)- (CA INDEX NAME)				

Absolute stereochemistry.
Double bond geometry as shown.




RN 880144-55-8 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2-amino-6-quinoliny) methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, (5Z)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 880144-54-7
 CMF C22 H18 N4 O S

Absolute stereochemistry.
Double bond geometry as shown.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 880144-62-7 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2-amino-4-ethoxy-6-quinoliny) methylene]-2-[(2-(3-fluorophenyl)ethyl]amino]- (CA INDEX NAME)



RN 880144-70-7 CAPLUS

CN Acetamide, N-[6-[(2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene)methyl]-4-ethoxy-2-quinolinyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:273695 CAPLUS
 DN 144:312080
 TI Preparation of thiazolinone 4-monosubstituted quinolines as CDK1-Cyclin B
 inhibitors for use as anti-cancer agents
 IN Chen, Li; Chen, Shaoqing; Sidduri, Achyutharao; Lou, Jianping
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 131 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006029861	A1	20060323	WO 2005-EP9925	20050915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US	20060063805	A1	20060323	US 2005-214153	20050829
US	7253285	B2	20070807		
AU	2005284292	A1	20060323	AU 2005-284292	20050915
CA	2579476	A1	20060323	CA 2005-2579476	20050915
EP	1797085	A1	20070620	EP 2005-787266	20050915
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN	101023080	A	20070822	CN 2005-80031330	20050915
JP	2008513396	T	20080501	JP 2007-531675	20050915
BR	2005015467	A	20080722	BR 2005-15467	20050915
MX	2007002914	A	20070427	MX 2007-2914	20070309
KR	2007043890	A	20070425	KR 2007-706017	20070315
KR	898533	B1	20090520		
IN	2007CN01148	A	20070817	IN 2007-CN1148	20070319
KR	2009031798	A	20090327	KR 2009-704698	20090305
PRAI	US 2004-610679P	P	20040917		
	WO 2005-EP9925	W	20050915		
	KR 2007-706017	A3	20070315		
OS	MARPAT 144:312080				
IT	879324-56-8P, (Z)-2-[(2-(2-Ethoxyphenyl)ethyl]amino]-5-[1-(4-ethoxyquinolin-6-yl)methylidene]thiazol-4-one				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(drug candidate; preparation of thiazolinone 4-monosubstituted quinolines as CDK1-Cyclin B inhibitors for use as anti-cancer agents)				
RN	879324-56-8 CAPLUS				
CN	4(5H)-Thiazolone, 2-[(2-(2-ethoxyphenyl)ethyl]amino]-5-[(4-ethoxy-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)				

Double bond geometry as shown.



IT 879323-75-8P, (Z)-5-(4-Methoxyquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879323-80-5P, (Z)-5-(4-Ethoxyquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879323-82-7P, (Z)-5-(4-Chloroquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879323-87-2P, (Z)-5-[4-(Cyclohexylmethoxy)quinolin-6-ylmethylidene]-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879323-89-4P, (Z)-5-(4-Diethylaminoquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879323-92-9P, (Z)-5-[4-(Morpholin-4-yl)quinolin-6-ylmethylidene]-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879323-96-3P, (Z)-5-[4-(2-Methoxyethoxy)quinolin-6-ylmethylidene]-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879324-10-4P, (Z)-2-[(2-Chlorobenzyl)amino]-5-(4-ethoxyquinolin-6-ylmethylidene)thiazol-4-one 879324-13-7P, (Z)-2-[(2-Chloro-6-methylbenzyl)amino]-5-(4-ethoxyquinolin-6-ylmethylidene)thiazol-4-one 879324-27-3P, (Z)-2-[(2-Chloro-4-fluorobenzyl)amino]-5-(4-ethoxyquinolin-6-ylmethylidene)thiazol-4-one 879324-29-5P, (Z)-5-(4-Phenoxyquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879324-30-8P, (Z)-5-(4-Butoxyquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879324-37-5P, (Z)-5-[4-Ethoxyquinolin-6-ylmethylidene]-2-[(4-hydroxyphenyl)ethyl]amino]thiazol-4-one 879324-39-7P, (Z)-5-[4-(2-Dimethylaminoethoxy)quinolin-6-ylmethylidene]-2-[(2-(3-fluorophenyl)ethyl)amino]thiazol-4-one 879324-41-1P, (Z)-2-[(2-(3-Fluorophenyl)ethyl)amino]-5-[4-(2,2,2-trifluoroethoxy)quinolin-6-ylmethylidene]thiazol-4-one 879324-45-5P, (Z)-5-(4-Ethylsulfanylquinolin-6-ylmethylidene)-2-[(1R,2S)-2-phenylcyclopropylamino]thiazol-4-one 879324-47-7P, (Z)-5-(4-Ethylsulfanylquinolin-6-ylmethylidene)-2-[(2-(3-fluorophenyl)ethyl)amino]thiazol-4-one 879324-54-6P, (Z)-5-[4-Ethoxyquinolin-6-yl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]thiazol-4-one 879324-58-0P, (Z)-2-[(2-(2-Ethoxophenyl)ethyl)amino]-5-[1-(4-ethoxyquinolin-6-yl)methylidene]thiazol-4-one mono(methanesulfonate) 879324-62-6P, (Z)-5-[1-(4-Ethoxyquinolin-6-yl)methylidene]-2-[(2-(4-fluorophenyl)cyclopropyl)amino]thiazol-4-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of thiazolone 4-monosubstituted quinolines as CDK1-Cyclin B inhibitors for use as anti-cancer agents)

RN 879323-75-8 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-methoxy-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropylamino]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 879323-80-5 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 879323-82-7 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-chloro-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 879323-87-2 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-(cyclohexylmethoxy)-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 879323-89-4 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-(diethylamino)-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 879323-92-9 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-(4-morpholinyl)-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 879323-96-3 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-(2-methoxyethoxy)-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 879324-10-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-[(4-ethoxy-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 879324-13-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-6-methylphenyl)methyl]amino]-5-[(4-ethoxy-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 879324-27-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)methyl]amino]-5-[(4-ethoxy-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 879324-29-5 CAPLUS

10/535,690

CN 4(5H)-Thiazolone, 5-[(4-phenoxy-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino-, (5Z)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 879324-30-8 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-phenoxy-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropyl]amino-, (5Z)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 879324-37-5 CAPLUS

CN 4(5H)-Thiazolone, 5-[(4-ethoxy-6-quinolinyl)methylene]-2-[(2-(4-hydroxyphenyl)ethyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 879324-39-7 CAPLUS


CN 4(5H)-Thiazolone, 5-[(4-[(2-(dimethylamino)ethoxy)-6-quinolinyl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 879324-41-1 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-(3-fluorophenyl)ethyl)amino]-5-[(4-(2,2,2-trifluoroethoxy)-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 879324-45-5 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(4-(ethylthio)-6-quinolinyl)methylene]-2-[(1R,2S)-2-phenylcyclopropylamino]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 879324-47-7 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(4-(ethylthio)-6-quinolinyl)methylene]-2-[(2-(3-fluorophenyl)ethyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



10/535,690

RN 879324-54-6 CAPLUS
CN 4(5H)-Thiazolone, 5-[(4-ethoxy-6-quinoliny)ethylene]-2-[2-(3-fluorophenyl)ethyl]amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 879324-58-0 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(2-ethoxyphenyl)ethyl)amino]-5-[(4-ethoxy-6-quinoliny)ethylene]-, (5Z)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 879324-56-8
CMF C25 H25 N3 O3 S

Double bond geometry as shown.



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 879324-62-6 CAPLUS
CN 4(5H)-Thiazolone, 5-[(4-ethoxy-6-quinoliny)ethylene]-2-[{2-(4-fluorophenyl)cyclopropyl}amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.

10/535,690



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:13243 CAPLUS
 DN 144:108310
 TI Thiazolinone 3,4-disubstituted quinolines as CDK1 inhibitors for treating cancer
 IN Chen, Li; Chen, Shaoqing; Michoud, Christophe
 PA Peop. Rep. China
 SO U.S. Pat. Appl. Publ., 66 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060004046	A1	20060105	US 2005-170450	20050629
	US 7250515	B2	20070731		
	AU 2005259511	A1	20060112	AU 2005-259511	20050623
	CA 2571732	A1	20060112	CA 2005-2571732	20050623
	WO 200600288	A1	20060112	WO 2005-EP6806	20050623
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1771443	A1	20070411	EP 2005-745044	20050623
	EP 1771443	B1	20090107		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
	CN 1976927	A	20070606	CN 2005-80021959	20050623
	JP 2008504323	T	20080214	JP 2007-518511	20050623
	BR 2005012843	A	20080408	BR 2005-12843	20050623
	AT 420086	T	20090115	AT 2005-745044	20050623
	ES 2317238	T3	20090416	ES 2005-745044	20050623
	ZA 2006010535	A	20090429	ZA 2006-10535	20061214
	MX 2006015026	A	20070208	MX 2006-15026	20061219
	KR 2007027656	A	20070309	KR 2006-727955	20061229
	KR 856363	B1	20080904		
	IN 2006CN04824	A	20071005	IN 2006-CN4824	20061229
	NO 2007000565	A	20070208	NO 2007-565	20070130
PRAI	US 2004-584931P	P	20040701		
	US 2005-658273P	P	20050303		
	WO 2005-EP6806	W	20050623		
OS	CASREACT 144:108310; MARPAT 144:108310				
IT	872576-61-9P		872577-25-8P		
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(drug candidate; preparation of thiazolinone disubstituted quinolines as CDK1 inhibitors for treating cancer)				
RN	872576-61-9	CAPLUS			
CN	3-Quinolinecarboxylic acid, 4-methoxy-6-[(Z)-4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl]-, methyl ester (CA INDEX NAME)				

Absolute stereochemistry.
Double bond geometry as shown.



RN 872577-25-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-cyano-6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



IT 872576-65-3P 872576-74-4P 872576-76-6P
 872576-77-7P 872576-80-2P 872576-85-7P
 872576-86-8P 872576-89-1P 872576-97-1P
 872577-10-1P 872577-23-6P 872577-26-9P
 872577-29-2P 872578-21-7P 872578-23-9P
 872578-24-0P 872578-37-5P 872578-48-8P
 872578-49-9P 872578-55-7P 872578-57-9P,
 6-[[2-(Cyclopropylamino)-4-oxo-4H-thiazol-5-ylidene]methyl]-4-[(piperidin-4-yl)oxy]quinoline-3-carbonitrile 872578-58-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of thiazolinone disubstituted quinolines as CDK1 inhibitors for treating cancer)

RN 872576-65-3 CAPLUS
 CN 3-Quinolinecarboxamide, 4-methoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 872576-74-4 CAPLUS

CN 3-Quinolinecarboxylic acid, 4-methoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 872576-76-6 CAPLUS

CN 3-Quinolinecarboxamide, N-[2-(dimethylamino)ethyl]-4-methoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

RN 872576-77-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 4-ethoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 872576-80-2 CAPLUS

CN 3-Quinolinecarboxamides, 4-methoxy-N,N-dimethyl-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 872576-85-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 4-methoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl]-, methyl ester, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● x HCl

RN 872576-86-8 CAPLUS

CN 3-Quinolinecarbonitrile, 4-ethoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 872576-89-1 CAPLUS

CN 3-Quinolinecarbonitrile, 4-ethoxy-6-[(Z)-[2-[(3-phenylcyclopropyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 872576-97-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-(3-fluorophenyl)ethyl)amino]-5-[(4-methoxy-3-(5-methyl-2-oxazolyl)-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872577-10-1 CAPLUS

CN 3-Quinolinecarbonitrile, 6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-ethoxy- (CA INDEX NAME)


Double bond geometry as shown.



10/535,690


RN 872577-23-6 CAPLUS
CN 3-Quinolincarbonitrile, 6-[(Z)-{2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene}methyl]-4-[2-(2-methoxyethoxy)ethoxy]- (CA INDEX NAME)

Double bond geometry as shown.



RN 872577-26-9 CAPLUS
CN 3-Quinolincarbonitrile, 6-[(Z)-{2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene}methyl]-4-(4-piperidinyloxy)-, hydrochloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 872577-29-2 CAPLUS
CN 3-Quinolincarbonitrile, 6-[(Z)-{2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene}methyl]-4-(1-methylethoxy)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872578-21-7 CAPLUS
CN 3-Quinolincarbonitrile, 6-[(Z)-{2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene}methyl]-4-(1-ethylpropoxy)- (CA INDEX NAME)

10/535,690


Double bond geometry as shown.



RN 872578-23-9 CAPLUS

CN 3-Quinolinecarbonitrile, 6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-(2-methylpropoxy)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872578-24-0 CAPLUS

CN 3-Quinolinecarbonitrile, 6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-(2,2-dimethylpropoxy)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872578-37-5 CAPLUS

CN 4(5H)-Thiazolone, 2-(cyclopropylamino)-5-[(4-ethoxy-3-(methylsulfonyl)-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




10/535,690

RN 872578-48-8 CAPLUS

CN 3-Quinolinecarbonitrile, 6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 872578-49-9 CAPLUS

CN 3-Quinolinecarbonitrile, 4-butoxy-6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 872578-55-7 CAPLUS


CN 3-Quinolinecarbonitrile, 6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-(2-methoxyethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



RN 872578-57-9 CAPLUS

CN 3-Quinolinecarbonitrile, 6-[(Z)-[2-(cyclopropylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-4-(4-piperidinyloxy)- (CA INDEX NAME)




RN 872578-58-0 CAPLUS

CN 3-Quinolincarboxamide, N-[2-(dimethylamino)ethyl]-4-methoxy-6-[(Z)-[4-oxo-2-[(1R,2S)-2-phenylcyclopropyl]amino]-5(4H)-thiazolylidene]methyl]-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:13215 CAPLUS
 DN 144:108309
 TI Thiazolinone unsubstituted quinolines as CDK1 inhibitors for treating solid tumors
 IN Chen, Li; Chen, Shaoqing
 PA Hoffmann-La Roche Inc., USA
 SO U.S. Pat. Appl. Publ., 38 pp.
 CODEN: USXXCO

DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20060004045	A1	20060105	US 2005-170300	20050629
US 7326786	B2	20080205		
AU 2005259512	A1	20060112	AU 2005-259512	20050623
CA 2571738	A1	20060112	CA 2005-2571738	20050623
WO 200600289	A1	20060112	WO 2005-EP6807	20050623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1765817	A1	20070328	EP 2005-753643	20050623
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1984909	A	20070620	CN 2005-8002247	20050623
BR 2005011390	A	20071204	BR 2005-11390	20050623
JP 2008054324	T	20080214	JP 2007-518512	20050623
MX 2006015028	A	20070208	MX 2006-15028	20061219
ZA 2006010785	A	20081029	ZA 2006-10785	20061220
KR 2007024679	A	20070302	KR 2006-727870	20061229
KR 866298	B1	20081031		
IN 2006CN04823	A	20071005	IN 2006-CN4823	20061229
NO 2007000564	A	20070315	NO 2007-564	20070130
PRAI US 2004-584746P	P	20040701		
US 2004-629495P	P	20041119		
WO 2005-EP6807	W	20050623		
OS CASREACT 144:108309; MARPAT 144:108309				
IT 872573-97-2P, 2-[(2-(4-Methoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872573-98-3P, 2-[(2-(3-Methoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872573-99-4P, 2-[(2-(2,5-Dimethoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872574-03-3P, 2-[(2-(2-Ethoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872574-04-4P, 2-[(2-Methoxybenzyl)amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872574-05-5P, 2-[(2-(2-Methoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872574-08-8P, 2-[(2-(4-Aminophenyl)ethyl]amino]-5-[1-(quinolin-6-yl)methyl-(Z)-ylidene]thiazol-4-one 872574-16-8P,				

2-[((1R,2S)-2-Phenylcyclopropyl)amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-47-5P,
 2-[(2-Fluoro-6-methoxybenzyl)amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-50-0P,
 2-[((1R,2R)-2-Hydroxycyclopentyl)amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-51-1P,
 2-[((1R,2R)-2-Hydroxycyclohexyl)amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-52-2P 872574-54-4P
 872574-60-2P, 2-[(S)-1-(3-Methoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-61-3P,
 2-[(S)-1-(4-Methoxyphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-62-4P,
 2-[(1-(4-Methylsulfonylphenyl)ethyl]amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one 872574-85-1P 872574-86-2P
 872574-87-3P 872574-89-5P 872574-90-8P
 872575-00-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiazolinone unsubstituted quinolines as CDK1 inhibitors for treating cancer)

RN 872573-97-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-(4-methoxyphenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872573-98-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-(3-methoxyphenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 872573-99-4 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2-(2,5-dimethoxyphenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-03-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-ethoxyphenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-04-4 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-methoxyphenyl)methyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 872574-05-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(2-methoxyphenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



10/535,690


RN 872574-08-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(4-aminophenyl)ethyl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-16-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1R,2S)-2-phenylcyclopropyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 872574-47-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-fluoro-6-methoxyphenyl)methyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 872574-50-0 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1R,2R)-2-hydroxycyclopentyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 872574-51-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(1R,2R)-2-hydroxycyclohexyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 872574-52-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[(1R,2S)-2-(hydroxymethyl)cyclopropyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 872574-54-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(1R,2R)-2-(hydroxymethyl)cyclopropyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 872574-60-2 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1S)-1-(3-methoxyphenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 872574-61-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1S)-1-(4-methoxyphenyl)ethyl]amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 872574-62-4 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1-[4-(methylsulfonyl)phenyl]ethyl)amino]-5-(6-quinolinylimethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-85-1 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-hydroxycyclopentyl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-86-2 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-hydroxycyclohexyl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-87-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(hydroxymethyl)cyclopropyl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-89-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1-(3-methoxyphenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 872574-90-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(1-(4-methoxyphenyl)ethyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 872575-00-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-phenylcyclopropyl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:979651 CAPLUS
 DN 143:286417
 TI Preparation of thiazolone compounds for inhibiting hYAK3 proteins
 IN Duffy, Kevin J.; Fitch, Duke M.; Goodman, Steven Neal; Hasegawa, Masaichi;
 Johnson, Neil W.; Kaspares, Jiri; Shaw, Antony N.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 162 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082901	A1	20050909	WO 2005-US6022	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1718642	A1	20061108	EP 2005-723757	20050224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	JP 2007523957	T	20070823	JP 2007-500992	20050224
	US 20070249599	A1	20071025	US 2006-590623	20060824
PRAI	US 2004-547543P	P	20040225		
	WO 2005-US6022	W	20050224		
OS	CASREACT 143:286417; MARPAT 143:286417				
IT	864274-24-8P 864274-25-9P		864274-26-0P		
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (inhibitor; preparation of thiazolone compds. for inhibiting hYAK3 proteins)				
RN	864274-24-8 CAPLUS				
CN	4(5H)-Thiazolone, 2-[(trans-4-hydroxycyclohexyl)amino]-5-[(2-methyl-6- benzoxazolyl)methylene]- (CA INDEX NAME)				

Relative stereochemistry.
 Double bond geometry unknown.




RN 864274-25-9 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-[(2-
 phenylethyl)amino]- (CA INDEX NAME)

10/535,690



RN 864274-26-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[(4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl)amino]ethyl]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:120737 CAPLUS
 DN 142:219270
 TI Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors

IN Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, David

PA Applied Research Systems Ars Holding N.V., Neth.

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011686	A1	20050210	WO 2004-EP51625	20040727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260836	A1	20050210	AU 2004-260836	20040727
	CA 2531140	A1	20050210	CA 2004-2531140	20040727
	EP 1648452	A1	20060426	EP 2004-766335	20040727
	EP 1648452	B1	20090722		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007500171	T	20070111	JP 2006-521581	20040727
	US 20070021447	A1	20070125	US 2004-565976	20040727
	NO 2006000573	A	20060203	NO 2006-573	20060203
PRAI	EP 2003-102313	A	20030728		
	WO 2004-EP51625	W	20040727		
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT					
OS	CASREACT	142:219270;	MARPAT	142:219270	
IT	1044645-58-0				
RL	PRPH (Prophetic)				
	(Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)				
RN	1044645-58-0	CAPLUS			
CN	4-Thiazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-[(phenylmethyl)imino]-, (2E,5Z)-	(CA INDEX NAME)			

Double bond geometry as shown.




10/535,690

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)


RN 843641-27-0 CAPLUS

CN 4(5H)-Thiazolone, 5-(1,3-benzodioxol-5-ylmethylene)-2-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 843641-28-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(phenylmethyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:467698 CAPLUS
 DN 141:38601
 TI Preparation of thiazolidinones for inhibiting hYAK3
 IN Hasegawa, Masaichi; Tang, Jun; Sato, Hideyuki
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 107 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004047760	A2	20040610	WO 2003-US37658	20031118
	WO 2004047760	A3	20041021		
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2507256	A1	20040610	CA 2003-2507256	20031118
AU	2003298693	A1	20040618	AU 2003-298693	20031118
EP	1567112	A2	20050831	EP 2003-796448	20031118
EP	1567112	B1	20081015		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR	2003016502	A	20051004	BR 2003-16502	20031118
CN	1742010	A	20060301	CN 2003-80109119	20031118
JP	2006509765	T	20060323	JP 2004-555721	20031118
NZ	539873	A	20080926	NZ 2003-539873	20031118
AT	411302	T	20081015	AT 2003-796448	20031118
ES	2315566	T3	20090401	ES 2003-796448	20031118
AP	1967	A	20090430	AP 2005-3304	20031118
IN	2005DN02002	A	20070202	IN 2005-DN2002	20050511
MX	2005005406	A	20050803	MX 2005-5406	20050520
NO	2005002928	A	20050817	NO 2005-2928	20050615
HK	1083443	A1	20090710	HK 2006-102181	20060217
US	20060293338	A1	20061228	US 2006-535690	20060410
PRAI	US 2002-428384F	P	20021122		
	WO 2003-US37658	W	20031118		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:38601


IT 701293-25-6P 701293-26-7P 701293-38-1P
 701293-78-9P 701293-80-3P 701294-12-4P
 701294-16-8P 701294-17-9P 701294-18-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of thiazolidinones for inhibiting hYAK3)

RN 701293-25-6 CAPLUS


CN 4-(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 701293-26-7 CAPLUS
CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-38-1 CAPLUS
CN 4(5H)-Thiazolone, 2-(1-naphthalenylamino)-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-78-9 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 701293-80-3 CAPLUS
CN Benzenesulfonamide, 4-[[[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]methyl]- (CA INDEX NAME)




RN 701294-12-4 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl)amino]-N-(2-pyridinyl)- (CA INDEX NAME)




RN 701294-16-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(4-(4-methyl-1-piperazinyl)phenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



RN 701294-17-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-(3-chlorophenyl)ethyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-18-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl)amino]ethyl]- (CA INDEX NAME)




OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:550296 CAPLUS
DN 95:150296
OREF 95:25143a,25146a
TI Synthesis and reactions of *cis*-3-(2-furyl)propenoyl isocyanate
AU Kutschy, Peter; Kristian, Pavol; Dandarova, Miloslava; Kovac, Jaroslav
CS Dep. Org. Chem., Slovak Inst. Technol., Bratislava, 880 37, Czech.
SO Collection of Czechoslovak Chemical Communications (1981), 46(5), 1160-6
CODEN: CCCCAK; ISSN: 0366-547X
DT Journal
LA English
OS CASREACT 95:150296
IT 79148-85-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 79148-85-9 CAPLUS
CN 4(5H)-Thiazolone, 5-(2-furanylmethylene)-2-[(phenylmethyl)aminol]-, (Z)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



L4 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1981:462050 CAPLUS
 DN 95:62050
 OREF 95:10479a,10482a
 TI Synthesis of 2-substituted 5-arylidenethiazolin-4-ones from
 α,β -unsaturated acyl isothiocyanates
 AU Kutschy, Peter; Dzurilla, Milan; Kristian, Pavol; Kutschyova, Kvetoslava
 CS Dep. Org. Chem., Slovak Inst. Technol., Bratislava, 880 37, Czech.
 SO Collection of Czechoslovak Chemical Communications (1981), 46(2), 436-45
 CODEN: CCCCAK; ISSN: 0366-547X
 DT Journal
 LA English
 OS CASREACT 95:62050
 IT 78374-69-3P 78374-70-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 78374-69-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-(2-furanylmethylene)- (CA INDEX
 NAME)



RN 78374-70-6 CAPLUS
 CN 4(5H)-Thiazolone, 5-(2-furanylmethylene)-2-[(phenylmethyl)amino]- (CA
 INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1973:432038 CAPLUS

DN 79:32038

OREF 79:5201a,5204a

TI Thiazole derivatives

PA Etablissements Clin-Byla

SO Fr., 72 pp.


CODEN: FRXXAK

DT Patent

LA French


FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 1604530	A	19711129	FR 1967-109263	19670606
BE 716140	A	19681104	BE 1968-716140	19680605
GB 1224546	A	19710310	GB 1968-1224546	19680605
ES 354732	A1	19700416	ES 1968-354732	19680606
US 3704296	A	19721128	US 1971-146832	19710525
PRAI FR 1967-109263	A	19670606		
IT 27472-97-5P	27473-65-0P	27473-68-3P		
RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)			
RN 27472-97-5 CAPLUS				
CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(5-nitro-2-furanyl)methylene]-(CA INDEX NAME)				



RN 27473-65-0 CAPLUS

CN 4(5H)-Thiazolone, 5-[(5-nitro-2-furanyl)methylene]-2-[(phenylmethyl)amino]-(CA INDEX NAME)




RN 27473-68-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)methyl]amino)-5-[(5-nitro-2-

10/535,690

furanyl)methylene]- (CA INDEX NAME)




OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L4 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1973:43466 CAPLUS
 DN 78:43466
 OREF 78:6879a,6882a
 TI Antibacterial substituted thiazolidin-4-ones
 IN Mousseron, Max J.
 PA Etablissements Clin-Byla
 SO U.S., 23 pp. Continuation-in-part of U.S. 3,678,041 (CA 77;114388c).
 CODEN: USXXAM


DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3704296	A	19721128	US 1971-146832	19710525
	FR 1604530	A	19711129	FR 1967-109263	19670606
PRAI	FR 1967-109263	A	19670606		
IT	27472-97-5P	27473-65-0P	27473-68-3P		
	RL: SPN (Synthetic preparation); PREP (Preparation)				
RN	27472-97-5 CAPLUS				
CN	4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(5-nitro-2-furanyl)methylene]- (CA INDEX NAME)				




RN 27473-65-0 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(5-nitro-2-furanyl)methylene]-2-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 27473-68-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)methylamino]-5-[(5-nitro-2-furanyl)methylene]- (CA INDEX NAME)

10/535,690



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L4 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1972:514388 CAPLUS

DN 77:114388

OREF 77:18849a,18852a

TI Antibacterial substituted 4-thiazolidineones

IN Mousseron, Max J.

PA Etablissements Clin-Byla

SO U.S., 21 pp.


CODEN: USXXAM

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3678041	A	19720718	US 1968-733808	19680603
PRAI FR 1972-9263	A	19720606		
IT 27472-97-5P	27473-65-0P	27473-68-3P		
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 27472-97-5	CAPLUS			
CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(5-nitro-2-furanyl)methylene]- (CA INDEX NAME)				




RN 27473-65-0 CAPLUS

CN 4(5H)-Thiazolone, 5-[(5-nitro-2-furanyl)methylene]-2-[(phenylmethyl)amino]-
(CA INDEX NAME)

RN 27473-68-3 CAPLUS


CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)methyl]amino]-5-[(5-nitro-2-furanyl)methylene]- (CA INDEX NAME)

10/535,690



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1971:111963 CAPLUS
DN 74:111963
OREF 74:18137a,18140a
TI Reaction of 2-formylbenzimidazole with thiazolidine series ketones
AU Chizhevskaya, I. I.; Marisheva, L. S.; Yatsevich, N. M.
CS Inst. Fiz.-Org. Khim., Minsk, USSR
SO Vestsii Akademii Navuk BSSR, Seryyya Khimichnykh Navuk (1970), (6), 78-81
CODEN: VBSKAK; ISSN: 0002-3590
DT Journal
LA Russian
IT 31409-53-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31409-53-7 CAPLUS
CN 4(5H)-Thiazolone, 5-((1H-benzimidazol-2-yl)methylene)-2-
[(phenylmethyl)amino]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1970:121519 CAPLUS

DN 72:121519

OREF 72:21855a,21858a

TI Antibacterial furfurylidene thiazolidinones

IN Mousseron, Max

PA Etablissements Clin-Byla

SO S. Africain, 92 pp.


CODEN: SFXXAB

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6803535		19690205		
	DE 1770583			DE	
	GB 1224546			GB	
PRAI FR			19670606		
IT	27472-97-5	27473-65-0	27473-68-3		
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)				
	(pesticidal activity of)				
RN	27472-97-5	CAPLUS			
CN	4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(5-nitro-2-furanyl)methylene]-(CA INDEX NAME)				



RN 27473-65-0 CAPLUS

CN 4(5H)-Thiazolone, 5-[(5-nitro-2-furanyl)methylene]-2-[(phenylmethyl)amino]-(CA INDEX NAME)




RN 27473-68-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)methyl]amino]-5-[(5-nitro-2-


10/535,690

furanyl)methylene]- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1960:91671 CAPLUS
DN 54:91671
OREF 54:17373f-i,17374a-c
TI Further degradation products of cephalosporin C. Isolation and synthesis
of 2-(4-amino-4-carboxybutyl)thiazole-4-carboxylic acid
AU Jeffery, J. D'A.; Abraham, E. P.; Newton, G. G. F.
CS Univ. Oxford, UK
SO Biochemical Journal (1960), 75, 216-23
CODEN: BIJOAK; ISSN: 0264-6021
DT Journal
LA Unavailable
IT 106474-11-7
 (Derived from data in the 6th Collective Formula Index (1957-1961))
RN 106474-11-7 CAPLUS
CN 4(5H)-Thiazolone, 5-(2-furanylmethylene)-2-[(3-iodophenyl)methyl]amino-
(CA INDEX NAME)




L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1960:91670 CAPLUS
 DN 54:91670
 OREF 54:17372i,17373a-f
 TI Thiazolidinones. I
 AU Vasa, M. L.; Trivedi, J. J.; Kshatriya, K. C.
 CS M. G. Sci. Inst., Ahmedabad
 SO Journal of the Indian Chemical Society (1959), 36, 648-50
 CODEN: JICSAH; ISSN: 0019-4522
 DT Journal
 LA Unavailable
 IT 78374-70-6P, 4-Thiazolidinone, 2-(benzylimino)-5-furfurylidene-
 100954-35-6P, 4-Thiazolidinone,
 2-(p-bromobenzylimino)-5-furfurylidene- 102704-48-3P,
 4-Thiazolidinone, 2-(benzylimino)-5-[(2-methoxy-1-naphthyl)methylene]-
 106474-11-7P, 4-Thiazolidinone,
 5-furfurylidene-2-(m-iodobenzylimino)- 108237-99-6P,
 4-Thiazolidinone, 2-[p-chlorobenzylimino]-5-furfurylidene-
 108240-14-8P, 4-Thiazolidinone,
 2-[o-chlorobenzylimino]-5-furfurylidene- 110194-96-2P,
 4-Thiazolidinone, 2-(p-bromobenzylimino)-5-[(2-methoxy-1-
 naphthyl)methylene]- 110195-10-3P, 4-Thiazolidinone,
 2-(m-iodobenzylimino)-5-[(2-methoxy-1-naphthyl)methylene]-
 110435-92-2P, 4-Thiazolidinone,
 2-[p-chlorobenzylimino]-5-[(2-methoxy-1-naphthyl)methylene]-
 110436-40-3P, 4-Thiazolidinone,
 2-[o-chlorobenzylimino]-5-[(2-methoxy-1-naphthyl)methylene]-
 RL: PREP (Preparation)
 (preparation of)
 RN 78374-70-6 CAPLUS
 CN 4(5H)-Thiazolone, 5-(2-furanylmethylene)-2-[(phenylmethyl)amino]- (CA
 INDEX NAME)




RN 100954-35-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(4-bromophenyl)methyl]amino]-5-(2-furanylmethylene)-
 (CA INDEX NAME)




RN 102704-48-3 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2-methoxy-1-naphthalenyl)methylene]-2-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 106474-11-7 CAPLUS
CN 4(5H)-Thiazolone, 5-(2-furanylmethylene)-2-[(3-iodophenyl)methylamino]- (CA INDEX NAME)



RN 108237-99-6 CAPLUS
CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)methylamino]-5-(2-furanylmethylene)- (CA INDEX NAME)




RN 108240-14-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methylamino]-5-(2-furanylmethylene)- (CA INDEX NAME)




RN 110194-96-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-bromophenyl)methylamino]-5-[(2-methoxy-1-naphthalenyl)methylene]- (CA INDEX NAME)




RN 110195-10-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(3-iodophenyl)methylamino]-5-[(2-methoxy-1-naphthalenyl)methylene]- (CA INDEX NAME)




RN 110435-92-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)methyl]amino]-5-[(2-methoxy-1-naphthalenyl)methylene]- (CA INDEX NAME)




RN 110436-40-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)methyl]amino]-5-[(2-methoxy-1-naphthalenyl)methylene]- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1956:56884 CAPLUS
DN 50:56884
OREF 50:10711f-g
TI 5-Arylidene-2- α -naphthylimino-4-thiazolidones and some of their derivatives. I
AU Das, Bhaskar; Rout, M. K.
CS Ravenshaw Coll., Cuttack
SO Journal of the Indian Chemical Society (1955), 32, 442-4
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA Unavailable
IT 857963-14-5P, 4-Thiazolidinone,
2-[2-(acetoxymercuri)-1-naphthylimino]-5-furfurylidene-
RL: PREP (Preparation)
(preparation of)
RN 857963-14-5 CAPLUS
CN 4-Thiazolidinone, 2-[2-(acetoxymercuri)-1-naphthylimino]-5-furfurylidene-
(5CI) (CA INDEX NAME)




L4 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1956:16331 CAPLUS
DN 50:16331
OREF 50:3406d-i
TI 2-(2-Naphthylimino)-4-thiazolidinone and its derivatives
AU Rout, M. K.; Mahapatra, G. N.
CS Utkal Univ., Cuttack, India
SO Journal of the American Chemical Society (1955), 77, 2427-8
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable
IT 312316-66-8P, 4-Thiazolidinone,
5-furfurylidene-2-(2-naphthylimino)-
RL: PREP (Preparation)
(preparation of)
RN 312316-66-8 CAPLUS
CN 4(SH)-Thiazolone, 5-(2-furanylmethylene)-2-(2-naphthalenylamino)- (CA
INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1956:12278 CAPLUS
DN 50:12278
OREF 50:2547d-g
TI Thiazolidinones. I. 2-(1-Naphthylimino)-4-thiazolidinone and its condensation products
AU Das, Bhaskar; Rout, M. V.
CS Ravenshaw Coll., Cuttack
SO Journal of Scientific & Industrial Research (1955), 14B, 16-18
CODEN: JSIRAC; ISSN: 0022-4456
DT Journal
LA Unavailable
IT 857963-64-5P, 4-Thiazolidinone,
5-furfurylidene-2-(1-naphthylimino)-
RL: PREP (Preparation)
(preparation of)
RN 857963-64-5 CAPLUS
CN 4(5H)-Thiazolone, 5-(2-furanylmethylene)-2-(1-naphthalenylamino)- (CA
INDEX NAME)



10/535,690

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	121.09	307.67

STN INTERNATIONAL LOGOFF AT 12:29:26 ON 16 OCT 2009